Inflammatory demyelinating neuropathies

Current Treatment Options in Neurology

Volumn 13, Issue 2, 2011, Pages 131-142

  Lopate, Glenn ^a   Pestronk, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB;

ACUTE KIDNEY FAILURE; ALOPECIA; ANEMIA; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; BONE MARROW SUPPRESSION; CATARACT; CEREBROVASCULAR ACCIDENT; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONGESTIVE HEART FAILURE; CUSHINGOID SYNDROME; CYTOPENIA; DEEP VEIN THROMBOSIS; DEMYELINATING NEUROPATHY; DEPRESSION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHROCYTE APLASIA; FEVER; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GUILLAIN BARRE SYNDROME; HEADACHE; HEART INFARCTION; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; INFECTION; INFERTILITY; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG EMBOLISM; MOOD DISORDER; MORNING DOSAGE; MYALGIA; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PHYSIOTHERAPY; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SIDE EFFECT; SKIN BRUISING; SPEECH THERAPY; STEM CELL TRANSPLANTATION; STEVENS JOHNSON SYNDROME; STOMACH ULCER; SYNCOPE; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 79955875204     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-011-0114-0     Document Type: Review

References (55)

1. Ropper AH, Wijdicks EFM, Truax BT: Guillain-Barré Syndrome. Philadelphia: Davis; 1991.
2. Hahn AF, Hartung H-P, Dyck PJ: Chronic inflammatory demyelinating polyradiculoneuropathy. In Peripheral neuropathy, edn 4th. By Dyck PJ, Thomas PK. Philadelphia: Elsevier Saunders; 2005:2221-2253.
3. Kuwabara S, Mori M, Ogawara K, et al.: Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001, 24:54-58. (Pubitemid 32038027)
4. Yuki N, Ang CE, Koga M, et al.: Clinical features and response to treatment in Guillain-Barré syndrome associates with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314-321. (Pubitemid 30141840)
5. Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321-328. (Pubitemid 27087596)
6. Simmons Z, Albers JW, Bromberg MB, Feldman EL: Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995, 118:359-368.
7. Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325:1482-1486.
8. Pestronk A, Chuquilin M, Choksi R: Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. J Neurol Neurosurg Psychiatry 2010, 81:726-730.
9. Greenwood RJ, Newsom-Davis J, Hughes RAC, et al.: Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 1:877-879. (Pubitemid 14132390)
10. The Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985, 35:1096-1104.
11. Osterman PO, Fagius J, Lundemo G, et al.: Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984, 2:1296-1299.
12. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987, 22:753-761.
13. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Appropriate number of plasma exchanges in Guillain-Barré Syndrome. Ann Neurol 1997, 41:298-306.
14. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992, 326:1123-1129.
15. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996, 46:100-103.
16. PSGBS-Study Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997, 349:225-230.
17. Dyck PJ, O'Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136-141. (Pubitemid 12162978)
18. Molenaar DSM, van Doorn PA, Vermeulen M: Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997, 62:388-390. (Pubitemid 27199113)
19. Lopate G, Pestronk A, Al-Lozi M: Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005, 62:249-254. (Pubitemid 40204746)
20. Muley SA, Kelkar P, Parry GJ: Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008, 65:1460-1464.
21. van Schaik IN, Eftimov F, van Doorn PA, et al.: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:245-253. This is the first controlled trial showing efficacy of pulsed high-dose steroids in the long-term (6 months) treatment of CIDP. Side effects were less than with daily steroids.
22. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993, 56:36-39. (Pubitemid 23062977)
23. Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838-845. (Pubitemid 24370922)
24. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996, 119:1067-1077.
25. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM: A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996, 243:280-285. (Pubitemid 26071992)
26. Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445-449. (Pubitemid 32172866)
27. Hughes R, Bensa S, Willison HJ, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195-201. (Pubitemid 32738144)
28. Hughes RA, Donofrio P, Bril V, ICE Study Group, et al.: Intravenous immune globulin (10% caprylatechromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136-144. This is the most recent and largest controlled trial for patients with CIDP, showing efficacy of HIG compared with placebo over the 48-week treatment course.
29. Hahn AF, Bolton CF, Pillay N, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. A double blind, sham-controlled, crossover study. Brain 1996, 119:1055-1066.
30. Dyck PJ, Daube J, O'Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461-465. (Pubitemid 16161945)
31. Korinthenberg R, Schessl J, Kirschner J, Monting JS: Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005, 116:8-14.
32. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004, 102:177-193.
33. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR: Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher 1999, 14:107-113. (Pubitemid 29530444)
34. Parry GJ, Steinberg JS (eds.): Guillain-Barré syndrome: from diagnosis to recovery. Saint Paul: AAN; 2007:109-146.
35. Dyck PJ, O'Brien P, Swanson C, et al.: Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985, 35:1173-1176. (Pubitemid 15003451)
36. Dalakas MC, Engel WK: Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981, 9:134-145. (Pubitemid 11120646)
37. Barnett MH, Pollard JD, Davies L, et al.: Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454-460. (Pubitemid 28145321)
38. Mahattanakul W, Crawford TO, Griffin JW, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996, 60:185-187. (Pubitemid 26044192)
39. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715-717. (Pubitemid 39100833)
40. Bedi G, Brown A, Tong T, Sharma R: Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010, 81:634-636.
41. Good JL, Chehrenama M, Mayer RF, et al.: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735-1738. (Pubitemid 28565266)
42. Gladstone DE, Prestrud AA, Brannagan 3rd TH: High dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerve Syst 2005, 10:11-16. (Pubitemid 40289577)
43. Lee DH, Linker RA, Paulus W, et al.: Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008, 37:406-409. This is the first study showing efficacy of subcutaneous HIG in CIDP. Importantly, the cost of the drug was about 50% less than the cost of intravenous HIG.
44. Magy L: Subcutaneous injections of polyvalent immunoglobulins as a maintenance therapy for intravenous immunoglobulin-responsive patients with chronic inflammatory demyelinating polyneuropathy [abstract]. J Peripher Nerv Syst 2008, 13:176.
45. Benedetti L, Briani C, Franciotta D, et al.: Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy; a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2010 Jul 16 (Epub ahead of print). This is the largest series of refractory CIDP patients to receive rituximab, many with concomitant hematologic disease (paraproteinemia or lymphoma). Of 13 patients, 9 responded and no major adverse events were noted.
46. Marsh EA, Hirst CL, Llewelyn JG, et al.: Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010, 257:913-919. This is the first series describing response to alemtuzumab in patients with refractory CIDP. However, side effects may limit usefulness.
47. Mahdi-Rogers M, Kazmi M, Ferner R, et al.: Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Periph Nerve Syst 2009, 14:118-124.
48. Oyama Y, Sufit R, Loh Y, et al.: Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007, 69:1802-1803. (Pubitemid 350059310)
49. Remenyi P, Masszi T, Borbenyi Z, et al.: CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007, 14:e1-e2. (Pubitemid 47106752)
50. Gürses N, Uysal S, Çetinkaya F, Íslek Í, Kalayci AG: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995, 27:241-243.
51. Wang R, Feng A, Sun W, Wen Z: Intravenous immunoglobulin in children with Guillain-Barré syndrome. J Appl Clin Ped 2001, 16:223-224.
52. Nevo Y, Pestronk A, Kornberg AJ, et al.: Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996, 47:98-102. (Pubitemid 26243867)
53. Connolly AM: Chronic inflammatory demyelinating polyneuropathy in childhood. Pediatr Neurol 2001, 24:177-182.
54. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA: Childhood chronic inflammatory demyelinating polyneuropathy: clinical course long-term outcome. Neuromuscul Disord 2000, 10:398-406. (Pubitemid 30433809)
55. Hattori N, Ichimura M, Aoki S, et al.: Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci 1998, 154:66-71. (Pubitemid 28123216)